|
|
 |
|
Viewing report
|
|
|
|
Antibody Engineering: Technologies, Applications, and Business Opportunities
Drug and Market Development Publishing, Jan 2001, Pages: 600
After a significant respite during the '80s and most of the '90s, the antibody field has made a comeback. Antibodies are finding applications as therapeutics, as drug delivery vehicles, in diagnostics and imaging, and in drug discovery research for both screening and validation of targets. Among 113 currently approved biotech products currently in the market, monoclonal antibodies form an extremely exciting and emerging business area, with 10 therapeutic antibodies and 5 diagnostic products in the market. Additionally, there are about 75 antibodies currently in clinical trials, constituting nearly 20% of all biotech drugs in development. Several factors have contributed to the current enthusiasm in the antibody drug market. First, the humanization of antibodies has increased the potential of efficacious antibody therapy and the elimination of Hama response. Second, various in vitro technologies, specifically phage display systems, have provided avenues to generate efficiently large panels of human antibodies with relative ease. Third, human genome sequencing and related data-mining information are facilitating a generation of increasing numbers of drug targets (that are being leveraged by the antibody generation companies) for drug discovery and target validation, as well as for generating antibody therapeutic and diagnostic products. D&MD's Market Analysis Report, Antibody Engineering: Technologies, Applications, and Business Opportunities, examines the genesis and progress of antibody engineering technologies, provides an in-depth review of the applications in therapeutic and diagnostic areas, and puts forward a comprehensive analysis of strategic licensing activities and commercial opportunities surrounding the antibody marketplace. Additionally, the Report provides information about the current industry players, as well as considers the strategic issues relating to the impact of monoclonal antibodies as renaissance products on the biopharmaceutical industry. Unique Benefits of This Report: Comprehensive summary of the history of recombinant antibody innovations, identifying the circumstances that led to today's industry Review of the key antibody technologies, including genomics and proteomics-based high-throughput systems, presenting their many attributes and impact on drug discovery Extensive coverage of the applications of antibody engineering and monoclonal antibody products in diagnostic and therapeutic areas, detailing the widespread significance of antibodies Detailed discussion of the antibody industry, featuring thorough analyses, trends, and outlooks in the dealings of over 280 global alliances In-depth company profiles of 30 pertinent companies, presenting the technologies, product pipelines, clinical development status, intellectual property estate, alliances, business outlook, and strategies of each Analysis of overall industry trends, current and future products, existing revenues and forecasts, and business prospects and competition, highlighting where the industry is going and potential areas of opportunity In-depth Company Profiles: AbgenixAffitech ASAlexion PharmaceuticalsAltarexAntisomaApplied Molecular EvolutionBioInventBiositeBiovationCambridge AntibodyTechnologyCelltech GroupCentocorCorixaCrucellEnzonEOS BiotechnologyGenentechIdec PharmaceuticalImCloneImmunogenImmunomedicsMedarexMedImmuneMillennium PharmaceuticalMorphosysProtein Design LabsSeattle GeneticsTanoxXenerexXoma
Customers who bought this item also bought
Antibody Therapeutics: Production, Clinical Trials, and Strategic Issues
Therapeutic Monoclonal Antibodies Markets
European Therapeutic Monoclonal Antibody Markets
Monoclonal Antibody Based Products - Global Strategic Business Report
Monoclonal Antibodies 2007: Competitive Landscape & Pipeline Insight
Monoclonal Antibody Therapies: Evolving Into A $30 Billion Market
Monoclonal Antibodies Report: 2008 Update
Antibody Therapeutics: Product Development, Market Trends, and Strategic Issues, Revised Edition
Monoclonal Antibodies Report Part I
Monoclonal Antibody Based Products - Global Trends
The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
|
|
|
|
